Basic information
Biomarker: TMEFF2
Biomarker subtype: gene
Clinical application: prognosis(unfavorable)
Histology type: endometrial carcinoma
Cohort characteristics
Country: Egypt
Region: Zagazig
Study type: prospective cohort study
Followed up time : 50 months (range from 25 to 60).
Cohort age: 78;42
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 120 | EC | 120 |
Sample information
Sample type : tissue
Clinical method: immunohistochemistry
Expression pattern : highly expression(>5)
Expression elevation: Staining intensity was scored as 0, 1, 2, and 3, The percentage of stained cells observed in the whole section, < 5%, 5–25%, 26–50%, 51–75%, and > 75%, was scored as 0, 1, 2, 3, and 4, respectively. The above two scores were multiplied to obtain the final score as follows: 0 to 2 (? ); 3 to 4, (+); 5 to 8 (++); and 9 to 12, (+++). We considered values below 5 as low expression and values equal to and larger than 5 as high
Disease information
Statictics: cutoff<55;cutoff>55
Cohort age: 78;42
Related information
Description: TMEFF2 was highly expressed in EC and were associated with a shortened survival rate, dismal outcome, and poor prognosis in EC patients
Approved symbol: TMEFF2
Approved name: transmembrane protein with EGF like and two follistatin like domains 2
Locus type: gene with protein product
HGNC ID: HGNC:11867
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11867
Symbol status: Approved
Alias symbols: TENB2 HPP1 TR TPEF CT120.2
OMIM: 605734
Omim link: https://www.omim.org/entry/605734
NCBI name: 23671
NCBI link: https://www.ncbi.nlm.nih.gov/gene/23671
Summary: This gene encodes a member of the tomoregulin family of transmembrane proteins. This protein has been shown to function as both an oncogene and a tumor suppressor depending on the cellular context and may regulate prostate cancer cell invasion. Multiple soluble forms of this protein have been identified that arise from both an alternative splice variant and ectodomain shedding. Additionally, this gene has been found to be hypermethylated in multiple cancer types. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]
Expression: Biased expression in prostate (RPKM 5.9), brain (RPKM 4.8) and 3 other tissues
NCBI gene expression https://www.ncbi.nlm.nih.gov/gene/23671#gene-expression
